Profusa, Inc. · NASDAQ:PFSA
Profusa — NorthView Acquisition — SPAC Merger (January 2024)
29 slides from Profusa's SPAC merger presentation, Jan 29, 2024
Slide 1: Q1 2024 Investor Presentation
NASDAQ: PFSA (NVAC) Q1 2024 INVESTOR PRESENTATION ”Leading the marriage of personal healthcare and AI - led real - time technology”
Slide 2: Disclaimer and Safe Harbor Statement
NASDAQ: PFSA (NVAC) DISCLAIMER AND SAFE HARBOR STATEMENT 2 This presentation (the “Presentation”) contains confidential information and is solely being made available on a confidential basis, and subject to the following provisions to a limited number of selected persons and/or institutions (each a
Slide 3: Who We Are
NASDAQ: PFSA (NVAC) WHO WE ARE 3 Profusa, Inc. is a commercial - stage company located in the Bay Area that has invested almost $100M over 10 years developing a new generation of bio - engineered sensors that empower the real - time monitoring of body chemistry. THREE ADVANCED PLATFORMS: TISSUE OXYG
Slide 4: Key Investment Highlights
NASDAQ: PFSA (NVAC) 4 KEY INVESTMENT HIGHLIGHTS • O 2 product validated and approved in EU for 2023 commercial launch • CGM product data compelling: seeking EU and US approvals • APAC Joint Venture with Tasly Pharma provides royalty stream and commercial access to large Asian markets • Low COGS and
Slide 5: Our Technology Model
NASDAQ: PFSA (NVAC) OUR TECHNOLOGY MODEL 5 Profusa Cloud Low maintenance, cost effective, AI adaptive personal health management platform Low - cost novel subcontainous biologically compatible hydrogel micro - sensor 9+ months functionality INJECTABLE HYDROGEL MICRO - SENSOR REUSABLE OPTICAL READER
Slide 6: How AI Drives Our Digital Healthcare Technology
NASDAQ: PFSA (NVAC) 6 HOW AI DRIVES OUR DIGITAL HEALTHCARE TECHNOLOGY • Machine learning to create algorithms for enhanced monitoring • Accounting for variations of the tissue composition for continuous accuracy while still using the single injectable sensor • Multiple calculations around other phys
Slide 7: Profusa Specific Growth Platforms
NASDAQ: PFSA (NVAC) PROFUSA 3 SPECIFIC GROWTH PLATFORMS Transformative Technology with Significant Commercial Opportunities OXYGEN PLATFORM: GLUCOSE PLATFORM: DATA PLATFORM: • Enables remote monitoring • Mass - adoption potential due to cost advantage • Wide - ranging applications • True enablement
Slide 8: CE-Marked Lumee Continuous Tissue Oxygen Monitoring
NASDAQ: PFSA (NVAC) CE - MARKED LUMEE TM CONTINUOUS TISSUE OXYGEN MONITORING 8 Charger
Slide 9: Lumee Oxygen Provides Real-Time Insights During Surgery
NASDAQ: PFSA (NVAC) Lumee TM OXYGEN PROVIDES REAL - TIME INSIGHTS DURING SURGERY VALIDATES PROFUSA TECHNOLOGY PLATFORM 9 Lumee Oxygen Index [ - ] Remove Sheath Baseline Therapeutic Interventions Note (1): J. Vasc. Surg., June 2015, Volume 61:6, 1501 - 10 Lumee Oxygen Platform reports local tissue ox
Slide 10: Oxygen Market Opportunity
NASDAQ: PFSA (NVAC) OXYGEN MARKET OPPORTUNITY 10 LARGE UNMET NEED • Monitoring of compromised tissue, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs – >$1.5bn market with ~3m patients • Chronic wounds (diabetic ulcers, pressure
Slide 11: Data Rich, Accessible, Low-Cost CGM for All
NASDAQ: PFSA (NVAC) DATA RICH, ACCESSIBLE, LOW - COST CGM FOR ALL 11 Profusa Cloud Reader Profusa’s CGM Solution Current CGM Pain Points x Overcomes foreign body response: > 270 days functionality New sensor required every 10 – 14 days x Simple hypodermic needle injection of sensor 180 - day solutio
Slide 12: Lumee Glucose Clinical Trial Demonstrated Safety & Functionality
NASDAQ: PFSA (NVAC) 12 LUMEE GLUCOSE CLINICAL TRIAL DEMONSTRATED SAFETY & FUNCTIONALITY • Clinical trial evaluated the safety and functionality of the glucose platform, sensor, reader and AI platform ⎼ 4 Clinical sites ⎼ Two European clinical sites • Two Asian clinical sites • 54 Subjects enrolled •
Slide 13: Differentiated, Best-in-Class CGM Solution
NASDAQ: PFSA (NVAC) DIFFERENTIATED, BEST - IN - CLASS CGM SOLUTION 13 Insertion apparatus Insertion apparatus Surgical insertion and removal Simple injection – hypodermic needle Sensor Functional Lifetime (days) Deployment Method Dexcom Medtronic Abbott Senseonics • Current CGM market share mostly i
Slide 14: Redefining >500M TAM
NASDAQ: PFSA (NVAC) REDEFINING >500M TAM FROM “CAN YOU AFFORD IT” TO “DO YOU NEED IT?” 14 Current CGM TAM Profusa TAM • Established benefit of CGM across diabetes spectrum • Woefully under - penetrated opportunity >1.5M CGM users >71M Diagnosed 107M At - risk patient monitoring (5) ≈27M Diagnosed (U
Slide 15: Commercialization Strategy – Lumee Glucose & Oxygen (EU/US)
NASDAQ: PFSA (NVAC) COMMERCIALIZATION STRATEGY – LUMEE TM GLUCOSE & OXYGEN (EU/US) 15 Profusa Commercial Team (Manage JV, Partner & Distributor Performance) COMMERCIAL PARTNERS Oxygen • High Volume Hospital Centers • Ambulatory Centers & Doctors’ Offices Glucose • Diabetes Centers, Endocrinology Pra
Slide 16: Anticipated Milestones, Catalysts
NASDAQ: PFSA (NVAC) ANTICIPATED MILESTONES, CATALYSTS 16 2024 2025 2026 Program Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Lumee TM Glucose Lumee TM Oxygen Q1 Q2 Human Validation Data Published Human Pivotal Studies US/EU/Asia CE/FDA Submission Process Glucose Commercialization & Revenues EU Commercialization and Reve
Slide 17: Use of Proceeds
NASDAQ: PFSA (NVAC) USE OF PROCEEDS 17 $8M - 10M Lumee TM Glucose ~$2.5 - 3M Lumee TM Oxygen ~$0.5 - 1M Operations Support ~$5 - 6M Clinical studies and regulatory submission Commercial partnerships and EU distribution EU/US commercial operational capabilities Commercial - readiness preparation Futu
Slide 18: Mission Driven Executive Management
NASDAQ: PFSA (NVAC) MISSION DRIVEN EXECUTIVE MANAGEMENT 18 Ben Hwang Ph . D . , – Chairman, CEO From his early exposure as an undergraduate research fellow at the lab of Leroy Hood at Caltech, where the automated DNA sequencer was developed, to bringing cutting edge life sciences tools to the market
Slide 19: Value Proposition – De-Risked Technology
VALUE PROPOSITION – DE - RISKED TECHNOLOGY 19 • Potential to change industry standard functionality from 14 to 90 days and eventually >270 days • ~10 years and ~$100M invested in developing technology. More than 88 global issued and 79 pending patents • Clinical (human data) and third - party valida
Slide 20: Transaction Overview
NASDAQ: PFSA (NVAC) 24.9% 56.3% 18.9% 27.7% 54.2% 18.2% TRANSACTION OVERVIEW 20 PRO FORMA COMMON OWNERSHIP ILLUSTRATIVE SOURCES AND USES 1 ILLUSTRATIVE PRO FORMA VALUATION 0% Redemptions 46% Redemptions Public holders Profusa holders SPAC sponsor 155.0 155.0 Profusa Shareholder Equity Rollover 9.3 5
Slide 21: Key Investment Highlights - Summary
NASDAQ: PFSA (NVAC) 21 KEY INVESTMENT HIGHLIGHTS - SUMMARY • Valuation aligned with significant upside potential • Compelling multi - product platform with 2024 revenue • Access to Asian market – Tasley JV and license/royalty agreement • Global TAM with high margin potential • AI driven capabilities
Slide 22: Investor & Media Relations: CORE IR
22 Investor & Media Relations: CORE IR Bret Shapiro brets@coreir.com NASDAQ: PFSA (NVAC)
Slide 23: Appendix & Risk Factors
NASDAQ: PFSA (NVAC) 23 APPENDIX & RISK FACTORS
Slide 24: Risk Factors
NASDAQ: PFSA (NVAC) RISK FACTORS Carefully consider the following risk factors, among others that will be contained in (or coordinated by reference into) the proxy statement / prospectus, related to Profusa’s business, reputation, financial condition, results of operations, revenue and the future pr
Slide 25: Risk Factors (Cont'd)
NASDAQ: PFSA (NVAC) RISK FACTORS (CONT’D) RISKS RELATED TO PROFUSA AND ITS INDUSTRY (Cont’d) Profusa faces substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than Profusa. If Profusa fails to develo
Slide 26: Risk Factors (Cont'd)
NASDAQ: PFSA (NVAC) RISK FACTORS (CONT’D) RISKS RELATED TO NORTHVIEW AND THE BUSINESS COMBINATION (Cont’d) If a stockholder fails to receive notice of our offer to redeem our public shares in connection with our business combination, or fails to comply with the procedures for tendering its shares, s
Slide 27: Risk Factors (Cont'd)
NASDAQ: PFSA (NVAC) RISK FACTORS (CONT’D) RISKS RELATED TO NORTHVIEW AND THE BUSINESS COMBINATION (Cont’d) Our executive officers and directors allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs . This con
Slide 28: Risk Factors (Cont'd)
NASDAQ: PFSA (NVAC) RISK FACTORS (CONT’D) RISKS RELATED TO NORTHVIEW AND THE BUSINESS COMBINATION (Cont’d) If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismiss
Slide 29: Risk Factors (Cont'd)
NASDAQ: PFSA (NVAC) RISK FACTORS (CONT’D) RISKS RELATED TO NORTHVIEW AND THE BUSINESS COMBINATION (Cont’d) We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least 65 % of the then outstanding public warrants .